Immutep (IMMP) Accounts Payables (2011 - 2025)
Immutep's (IMMP) quarterly Accounts Payables came in at $29.9 million in Q4 2025, up 524.95% YoY from $4.8 million in Q4 2024, and up 338.68% on a QoQ basis from $6.8 million in Q2 2025.
Immutep (IMMP) Accounts Payables (2011 - 2025) Analysis & Trends
Immutep (IMMP) has 15 years of Accounts Payables data on file, last reported at $29.9 million in Q4 2025.
- Quarterly Accounts Payables rose 524.95% year-over-year to $29.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $29.9 million (up 524.95% YoY) and the FY2025 annual result came in at $6.8 million, up 8.08% from the prior year.
- Accounts Payables advanced to $29.9 million in Q4 2025, from $6.8 million in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $29.9 million in Q4 2025 to a low of $3.7 million in Q2 2021.
- A 5-year average of $7.6 million and a median of $5.2 million in 2022 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2023 — Accounts Payables declined 25.99% — and 2025, when it jumped 524.95%.
- Tracing IMMP's Accounts Payables over 5 years: stood at $5.3 million in 2021, then decreased by 2.28% to $5.2 million in 2022, then decreased by 25.99% to $3.8 million in 2023, then gained by 25.03% to $4.8 million in 2024, then jumped by 524.95% to $29.9 million in 2025.
- The last three Accounts Payables figures came in at $29.9 million (Q4 2025), $6.8 million (Q2 2025), and $4.8 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Immutep | 56.46 Mn | -8.63 Mn | - | 29.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 29.88 Mn |
| Jun 30, 2025 | 6.81 Mn |
| Dec 31, 2024 | 4.78 Mn |
| Jun 30, 2024 | 6.30 Mn |
| Dec 31, 2023 | 3.82 Mn |
| Jun 30, 2023 | 6.03 Mn |
| Dec 31, 2022 | 5.17 Mn |
| Jun 30, 2022 | 4.12 Mn |
| Dec 31, 2021 | 5.29 Mn |
| Jun 30, 2021 | 3.68 Mn |
| Dec 31, 2020 | 3.49 Mn |
| Jun 30, 2020 | 1.92 Mn |
| Dec 31, 2019 | 2.47 Mn |
| Jun 30, 2019 | 3.54 Mn |
| Dec 31, 2018 | 2.85 Mn |
| Jun 30, 2018 | 1.22 Mn |
| Jun 30, 2017 | 1.94 Mn |
| Mar 31, 2017 | 922,578.89 |
| Jun 30, 2016 | 1.06 Mn |
| Jun 30, 2015 | 2.15 Mn |